Medical application of CREG protein in prevention or treatment of diabetic cardiomyopathy

A technology for diabetic cardiomyopathy and protein is applied in the preparation of drugs for preventing or treating diabetic cardiomyopathy and related diseases. In the field of CREG protein, it can solve problems such as unclear function and mechanism of CREG protein.

Pending Publication Date: 2020-06-09
GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role and mechanism of CREG protei

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of CREG protein in prevention or treatment of diabetic cardiomyopathy
  • Medical application of CREG protein in prevention or treatment of diabetic cardiomyopathy
  • Medical application of CREG protein in prevention or treatment of diabetic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 High-fat diet combined with low-dose streptozotocin (STZ) to establish a DCM model in C57BL / 6J mice and detection of CREG protein and autophagy-lysosomal protein expression in myocardial tissue

[0039] ①Establishment of DCM model in C57BL / 6J mice

[0040] Using the random table method, 40 male 8-week-old C57 BL / 6 mice were divided into the following two groups: normal feeding group (ND) and high-fat feeding combined with STZ group (HFD+STZ), 20 in each group. The normal feeding group is fed with normal diet feed (3.85kcal / g, fat provides 10% of calories, U.S. Research Diet company), and the HFD+STZ group is fed with high-fat feed (5.24kcal / g, fat provides 60% of calories, U.S. Research Diet company), after 4 weeks of feeding, a small dose of STZ (25mg / kg.d) was given for 5 consecutive days, and the high-fat feeding continued until 24 weeks. The mice were fed with standard feeding conditions, received 12 hours of light, and did not limit the amount of food an...

Embodiment 2

[0079] Example 2 Establishment of CREG-overexpressed CREG transgenic mice (CREG-TG) and detection of CREG expression in myocardial tissue

[0080] ① Genotype identification of CREG-TG mice: CREG-TG mice were established through the Southern Model Animal Center in Shanghai, China. Use the PCR-Genotyping method to carry out genotyping and identification according to the following reaction system and conditions

[0081]

[0082] PCR reaction system: (25μl)

[0083]

[0084] PCR reaction conditions: The above reaction system was amplified by conventional touchdown PCR procedure.

[0085] The results showed that two pairs of primers were used to identify the mouse genotype. When bands were amplified by both pairs of primers, the mouse was CREG-TG, and when bands were not amplified by both pairs of primers, the mouse was wild type. Among them, No. 1 is a negative control, and No. 2 is a positive control. According to the PCR results, it can be seen that No. 4, No. 7 and No...

Embodiment 3

[0095] Example 3 CREG-TG mice can improve myocardial diastolic and systolic functions, myocardial fibrosis and myocardial autophagy after DCM

[0096] ① Body weight and fasting blood glucose level of CREG-TG mice after DCM model

[0097] The methods for establishing DCM models of CREG-TG mice and WT mice are detailed in Example 1. High-fat feeding continued until 24 weeks. The mice were fed with standard feeding conditions, received 12 hours of light, and did not limit the amount of food and water they drank. 6 in each group. Monitor body weight and fasting blood glucose every 2-4 weeks. Food and water were fasted for 12 hours before weighing. Each mouse was weighed 3 times, recorded and averaged.

[0098] The results showed that compared with the ND group, whether it was WT mice or CREG-TG mice, the body weight of the HFD+STZ group began to be higher than that of the ND group when fed with a high-fat diet for 4 weeks. The weight gain of the mice in the STZ group was mor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of cellular repressor of ElA-stimulated gene (CREG) protein, in particular to application of CREG protein and an active fragment thereof in preparation of drugs for preventing and/or treating diabetic cardiomyopathy and related diseases thereof. The invention further relates to application of a recombinant vector or a recombinant cell for expressing the CREG protein or the active fragment thereof in preparation of drugs for preventing and/or treating the diabetic cardiomyopathy and the related diseases thereof.

Description

technical field [0001] The present invention relates to the medical use of E1A activated gene repressor gene (Cellular Repressor of E1A-stimulated Genes, CREG), in particular to the use of CREG protein for preparing medicines for preventing or treating diabetic cardiomyopathy and related diseases. Background technique [0002] Diabetes mellitus is a metabolic disease characterized by chronic elevated blood sugar, mainly divided into type 1 and type 2, of which type 2 diabetes is particularly common. Type 2 diabetes is mainly characterized by insulin resistance with or without β-cell dysfunction. Diabetes is widely prevalent in the world. The World Health Organization reports that by 2025, the number of people with diabetes worldwide will reach 550 million, and the global incidence of type 2 diabetes is 5.4%. According to the diabetes epidemiological survey conducted by the Diabetes Society of the Chinese Medical Association, there were more than 100 million type 2 diabetes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61K45/00A61P3/10A61P9/00G01N33/68C12Q1/6883
CPCA61K38/1709A61K45/00A61P3/10A61P9/00G01N33/6893C12Q1/6883C12Q2600/158G01N2800/325G01N2800/56
Inventor 韩雅玲刘丹田孝祥闫承慧邢瑞楠齐艳萍
Owner GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap